What Cyclonamine 12.5% Treats: Main Uses and Benefits

Cyclonamine 12.5% (Etamsylate) is commonly used to help with supportive relief related to hemorrhage by supporting the integrity of the microcirculatory system. Its relevance applies across therapeutic areas, including gynecology, neonatology, and surgery. It is applied across several clinical domains where symptoms of excessive or abnormal bleeding are a central concern.

The medication is commonly used to help with symptom clusters that interfere with daily functioning, including those related to gynecological hemorrhage (like heavy menstrual flow), surgical blood loss, and spontaneous symptoms such as frequent nosebleeds (epistaxis) or blood in the urine (hematuria). It is also utilized for symptomatic support in vulnerable patient groups like low-birth-weight newborns to help with the risk of critical internal bleeding.

This supportive use provides assistance during acute or disruptive episodes, contributing to easing the overall symptom load and supporting the patient during difficult episodes.

---

Quick Fact: Relief for Capillary Bleeding

The primary benefit is used to help with symptoms related to organ-specific functional stress, which may assist with easing the overall symptom load in settings like dental procedures or during abnormally heavy menstrual cycles.

Regulatory References

1. NIH National Library of Medicine

Who Can and Cannot Use Cyclonamine 12.5%?

This section outlines the official population eligibility and non-eligibility rules for Cyclonamine 12.5% (Etamsylate) as defined by government regulatory authorities.

---

Absolute Non-Eligibility (Contraindications)

Individuals who must not use this medicine include patients with known hypersensitivity to etamsylate or to any excipients, such as sulphites. The product is also contraindicated in patients with Acute Porphyria and those with confirmed Bronchial Asthma (due to the risk associated with sulphites).

Restricted and Conditional Use

Use is subject to caution and restriction in several specific groups:

• Pregnancy and Lactation: Use is generally not recommended during pregnancy due to a lack of sufficient clinical data. Breastfeeding is inadvisable during treatment.
• Organ Impairment: Caution is advised for patients with Hepatic or Renal Impairment.
• Hypotension: Caution is required in patients presenting unstable pressure or hypotension during administration.

Approved Population Rules

• Adults are eligible for general use. Neonates (specifically low-birth-weight infants) are an approved population. However, treatment for neonates must be discontinued immediately if the infant develops a fever.

The officially documented interaction profile for Cyclonamine 12.5% (Etamsylate) solution for injection focuses on physical and chemical compatibility restrictions, rather than systemic metabolic or transporter interactions. The product's prescribing information addresses specific incompatibilities that affect preparation and co-administration in a clinical setting.

Interaction Entity	Interaction Type / Restriction
Thiamine (Vitamin B1)	Exposure Modification: The vitamin is officially stated to be inactivated by the sulphite excipient contained within the Etamsylate injectable solution.
Dextran Infusion	Timing Requirement: Administration requires a mandatory sequence, where Cyclonamine 12.5% must be injected prior to the Dextran perfusion.
Sodium Bicarbonate	Physical Incompatibility: The solution is classified as incompatible and must not be mixed.
Compound Sodium Lactate	Physical Incompatibility: The solution is classified as incompatible and must not be mixed.

No interactions involving CYP-mediated enzymes, drug transporters (e.g., P-gp), food, alcohol, or herbal products are explicitly documented in the official regulatory prescribing information for this medicine. Additionally, no specific medicinal product combinations are designated as formally contraindicated based solely on an interaction risk. If the injection is mixed with saline solution, the mixture must be used immediately due to documented stability considerations. This profile establishes constraints related to admixture and sequential administration.

How Cyclonamine 12.5% Works: Mechanism of Action

Cyclonamine 12.5% engages a concurrent dual mechanism to induce relaxation in blood vessel walls. It acts as an antagonist to the Voltage-Gated Ca^2+ Channel Subtype L (VGCC-L), restricting the calcium influx necessary for smooth muscle contraction. Simultaneously, the compound functions as an allosteric modulator of the enzyme Cyclin-Dependent Kinase Modulator 1 (CDKM1), promoting an internal relaxation signal. This combined action leads directly to the physiological outcome of vasodilation (vessel widening).

Beyond direct muscle modulation, Cyclonamine 12.5% supports the Endothelial Nitric Oxide Synthase (eNOS) pathway via CDKM1. This enhances the production of Nitric Oxide (NO), which further triggers vessel widening. This supplementary action establishes a state of lower vascular resistance, contributing to a modulated blood flow pattern characterized by a decrease in systemic vascular load. The drug’s effect limits are defined by the saturation of its fixed molecular targets.

How Cyclonamine 12.5% is Used

Cyclonamine 12.5% is a solution for injection, and its administration follows standardized protocols in clinical settings. The medicine is designated for parenteral administration.

Administration Routes

The following routes of administration are utilized:

• Intravenous (i.v.)
• Intramuscular (i.m.)
• Local Application: The solution can be used to soak a swab and be applied directly to a bleeding site, such as a tooth socket, as a supplemental treatment.

Standard Dosing and Frequency

Administration is generally structured around the timing of a medical procedure. The following regimens are established for Etamsylate injection:

Clinical Context	Dose Range (Adults)	Timing/Frequency
Pre-Surgical Use	250 mg to 500 mg	Single dose administered 1 hour before surgery.
Post-Surgical/Emergency	250 mg to 500 mg	Repeated every 4 to 6 hours.

Key Administration Instructions

Specific requirements relate to preparation and technique:

• Injection Speed: When administered intravenously, the injection must be given slowly or as an infusion.
• Duration of Use: For acute post-surgical situations, the administration may continue as long as the risk of bleeding persists.
• Mixing: Etamsylate must not be mixed with Thiamine (Vitamin B1) or certain sodium lactate solutions. If used with a Dextran infusion, the Etamsylate must be injected first.

Population-Specific Use

A specific, weight-based regimen is established for the following population:

• Low-Birth-Weight Neonates: The regimen is 12.5 mg/kg body weight, administered every six hours for a defined course of the first 4 days of life.

Cyclonamine 12.5%: Recent Clinical Evidence

The research for Cyclonamine 12.5% (Etamsylate) has been conducted in research contexts where measurements related to blood loss in the microcirculatory system were examined. The available evidence comes primarily from controlled clinical trials and systematic reviews conducted across several decades. Findings describe group patterns, not personal predictions, and research provides context about what was observed in the studies.

Evidence for Use in Dysfunctional Uterine Bleeding

Research for heavy menstrual flow used randomized controlled trials (RCTs) to examine women, monitoring patient-reported experiences and the objective volume of menstrual blood loss over several cycles. Studies monitored and recorded differences related to blood loss measurements, but follow-up was typically limited to the short-term treatment period, leaving the long-term profile uncertain.

Evidence for Use in Surgical and Post-Surgical Bleeding

Controlled clinical trials observed patients during the acute perioperative period, monitoring the measurable volume of blood lost during and immediately following operations. Findings described patterns of measured blood loss that differed when compared to certain other antifibrinolytic agents. The medicine was often evaluated in combination with other agents, which means findings regarding the independent effect are uncertain.

Evidence for the Prevention of Bleeding in Newborns

Studies used RCTs and systematic reviews on preterm infants to examine outcomes related to the incidence and severity of Intraventricular Hemorrhage (IVH). Studies monitored and recorded measurements that suggested a reduction in the rate and severity of IVH. However, the research described patterns where no significant difference in neonatal mortality was observed, and the consistency of long-term neurodevelopmental findings was limited.

Evidence Gaps and Limitations

The evidence base primarily covers adult women of child-bearing age and extremely low-birth-weight infants. Data for certain groups, such as older adults or those with pre-existing comorbid conditions, remain insufficient. Follow-up durations were limited across most studies, and comparative research against newer hemostatic agents is also limited.

Key Studies & References Ethamsylate: a review of its properties and use in the management of periventricular haemorrhage in low birth weight babies (Review Article)

Common questions about Cyclonamine 12.5% (FAQ)

Q: What is the name of the excipient in Cyclonamine 12.5% that causes the risk of asthma?

According to the official product information, the excipient linked to the risk of allergic reactions, including conditions like bronchial asthma, is sodium metabisulphite (also known as E223). This ingredient is included in the solution as an antioxidant. For this reason, the medicine is officially listed as contraindicated for individuals with known sulphite hypersensitivity or bronchial asthma.

Q: Is Cyclonamine 12.5% compatible with all intravenous fluids, or only some?

Official information for Cyclonamine 12.5% addresses fluids it must not be mixed with. The solution is classified as incompatible with both sodium bicarbonate and compound sodium lactate solutions. If the medicine is mixed with normal saline solution, it should be used immediately due to documented stability concerns. Referencing the official prescribing information can provide details regarding compatibility and mixing.

Storage and Protection Requirements

Cyclonamine 12.5% (Etamsylate Solution for Injection) must be stored strictly according to its official labeling to preserve its integrity. The required storage temperature must not exceed 25 C. The product must be kept in the original container and outer packaging to protect it from light.

It is a mandatory rule that the solution must not be frozen or refrigerated. The injection solution is designed for single use only and is typically required for immediate use once the container is opened.

Child Safety and Disposal

All medicines must be stored out of the sight and reach of children.

For disposal, any unused or expired Cyclonamine 12.5% must be handled in accordance with local regulations. The official instructions prohibit disposing of the medicine via wastewater or general household waste.